Australia-China Biotech Invest 2017, page-6

Morning
Yes lots of truths there from @ClownTrader - good post mate!
At this stage of the game @Tech goose the
U.S hospitals are only testing children:

Inclusion Criteria;
Infant or child aged 29 days - 12 years

Purpose:
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in diagnosis of pneumonia and other respiratory conditions (bronchiolitis, asthma, croup, upper or lower respiratory tract infections) in infants and children. Patient's cough sounds will be recorded using a smartphone and analysed using the ResAppDx software. The ResAppDx diagnosis will be compared to radiologic diagnosis and/or clinical diagnosis. The ResAppDx diagnosis will not be provided to the clinician or patient.

https://www.clinicaltrials.gov/ct2/show/NCT02973282?term=Resapp&rank=1

Adult study will commence shortly is what I've been told...
The beauty of the current study is that it is testing a broad range of respiratory diseases and with our extended 2 year collaboration with MGH one can only assume other new discoveries will be found too ..

Cheers

Red bar